Injection technology company PharmaJet revealed on Tuesday that its Needle-free Injection System (NFIS) will be used in a clinical trial that will deliver a booster vaccine against COVID-19 virus variants.
The vaccine is reportedly developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK,
Under the University of Cambridge's Phase 1 clinical trial, the COVID-19 vaccine will be delivered exclusively with the PharmaJet Tropis Needle-free injection system, which was selected based on its ability to increase the efficacy of nucleic acid-based vaccines and therapeutics.
This is the 20th COVID-19 vaccine development programme using PharmaJet Needle-free Injection Systems as their method of delivery.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients